REVIVE THERAPEUTICS LTD News

Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Revive Therapeutics (RVV.CN), a specialty life sciences company, on Thursday announced that the U.S. Food and Drug Administration has assigned it a meeting date of June 7. Revive had requested a meeti

MT NewswiresApr 18 06:57

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireMar 27 08:08

Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireMar 19 06:00

Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation

Seeking AlphaMar 7 10:29

Oregon House Passes Bill to End Hard Drug Decriminalization

There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.

Seeking AlphaMar 1 05:42

Press Release: Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110

Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO

Dow JonesFeb 26 15:05

Psychedelic Stocks Gain After FDA Priority Review for MDMA Therapy

Seeking AlphaFeb 12 11:13

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireFeb 1 06:30

Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- REVIVE

GlobeNewswireJan 31 16:06

Revive Therapeutics Announces Offering of up to $3 Million

Seeking AlphaJan 25 03:10

Revive Therapeutics Ltd. Announces Offering of Up to $3 Million

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- REVIVE

GlobeNewswireJan 24 16:55

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure With Defence Research and Development Canada

Yahoo FinanceJan 16 06:00

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

Yahoo FinanceJan 10 06:00

Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

TORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireDec 20, 2023 11:54

Revive Therapeutics Collaborates With Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine

TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireDec 18, 2023 06:00

Revive Therapeutics Enters Into Worldwide Exclusive Agreement With Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company")

GlobeNewswireNov 6, 2023 06:45

Revive Therapeutics Enters Into Agreement With Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireOct 17, 2023 06:00

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireOct 11, 2023 07:50

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

TORONTO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of

GlobeNewswireAug 22, 2023 05:30

Revive Says Phase 3 Trial for Oral COVID Drug Failed

Seeking AlphaJul 6, 2023 06:05